BioNexus Gene Lab
BGLC
6 hedge funds and large institutions have $49.8K invested in BioNexus Gene Lab in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
50% more funds holding
Funds holding: 4 → 6 (+2)
0.03% more ownership
Funds ownership: 0.07% → 0.1% (+0.03%)
14% less capital invested
Capital invested by funds: $58.2K → $49.8K (-$8.41K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$10.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.67K |
| 3 |
JP Morgan Chase
New York
|
+$191 |
| 4 |
Morgan Stanley
New York
|
+$191 |
| 5 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
+$135 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $30.7K | +$8.67K | +2,632 | +32% |
|
|
XT
2
XTX Topco
George Town,
Cayman Islands
| $9.17K | +$10.8K | +3,283 | New |
|
3
Geode Capital Management
Boston,
Massachusetts
| $6.61K | – | – | – |
|
|
SRL
4
Scientech Research LLC
Jersey City,
New Jersey
| $3.02K | +$135 | +41 | +4% |
|
|
5
JP Morgan Chase
New York
| $162 | +$191 | +58 | New |
|
|
6
Morgan Stanley
New York
| $162 | +$191 | +58 | New |
|
|
7
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$6K | -1,296 | Closed |
|
BGLC Hedge Fund Activity: Q4 2024 in Review
6 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q4 2024, worth a combined $49.8K — down 14% from $58.2K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BGLC positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $10.8K. The largest seller was Cambridge Investment Research Advisors, exiting entirely with an estimated $6K sold.
- 6 institutional investors held BioNexus Gene Lab (BGLC) as of Q4 2024, up from 4 in Q3 2024.
- Funds reported $49.8K of BioNexus Gene Lab stock for Q4 2024, down 14% quarter-over-quarter.
- 3 funds opened new BioNexus Gene Lab positions in Q4 2024 and 1 closed out, a net change of +2 holders.
- The largest BioNexus Gene Lab buyer in Q4 2024 was XTX Topco, an estimated $10.8K added.
- The largest BioNexus Gene Lab seller in Q4 2024 was Cambridge Investment Research Advisors, an estimated $6K sold.
Based on aggregated 13F filings for Q4 2024.